JACKSONVILLE, Fla., Jan. 22 /PRNewswire-FirstCall/ -- Phlo Corporation (“Phlo”), which has acted as its own transfer agent since 2002, has announced today that it is moving the transfer agent function to an independent, outside firm. Phlo released this information in response to inquiries regarding the status of the transfer agent. Phlo expects its new transfer agent to be Continental Stock Transfer & Trust Company. Phlo has executed documentation pertinent thereto and is engaged in a process with Continental to put transfer records in electronic form.
Phlo is a biotechnology company and a manufacturer and marketer of products (primarily liquids) containing patented and patent-pending biotechnologies. Phlo is focusing its technology generation and acquisition efforts on those technologies related to enhancing cognition and personal performance, reducing the effects of aging, and preventing or ameliorating cancer.
Certain statements made herein that are not historical constitute “forward-looking” statements within the meaning of the Private Litigation Reform Act of 1995 and may contain words such as “anticipate,” “believe,” “expect,” “future,” “may,” “will,” “should,” “plan,” “projected,” “intend,” and similar expressions to identify such forward-looking statements. Such statements are based on a number of assumptions and on information and estimates supplied to Phlo Corporation by sources currently available to it. Such assumptions and estimates are subject to uncertainties, contingencies, and other factors, many of which are beyond Phlo Corporation’s control. Actual results may differ materially from the statements set forth above.
Phlo Corporation
CONTACT: James B. Hovis, Phlo Corporation, +1-973-691-9012
